Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204267 | 1.00 | BMP1 (0.41) | BMP1PSMB8PSMB5MMP7ITGAV | |
| SCHEMBL2204277 | 0.86 | BMP1 (0.46) | BMP1PSMB8PSMB5MMP7ITGAV | |
| SCHEMBL2201978 | 0.84 | BMP1 (0.43) | BMP1PSMB8ITGAVMMP1ITGB3 | |
| SCHEMBL4177600 | 0.81 | PSMB8 (0.48) | PSMB8PSMB5 | |
| SCHEMBL4177606 | 0.81 | PSMB8 (0.48) | PSMB8PSMB5 | |
| SCHEMBL6440140 | 0.71 | AVPR1B (0.48) | AVPR1BAVPR1A | |
| SCHEMBL14047889 | 0.69 | BMP1 (0.36) | BMP1 | |
| SCHEMBL6394294 | 0.67 | ITGAV (0.45) | BMP1ITGAV | |
| SCHEMBL10118749 | 0.67 | BRD4 (0.43) | — | |
| SCHEMBL7354160 | 0.67 | ITGAV (0.47) | ITGAVMMP1ITGB3ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| EP-2344457-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010049146-A1 | SUBSTITUTED SPIROAMINES | Grünenthal GmbH (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | BMP1 1617/4885PSMB8 1516/4885PSMB5 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.